This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

CEO Clips - Cannara Biotech Expands Cannabis Production with Mega Facilities

B-TV.com - Wed Mar 18, 6:14PM CDT
CEO Clips - Cannara Biotech Expands Cannabis Production with Mega Facilities

Vertically integrated producer scales capacity to meet growing demand

How is Cannara Biotech scaling cannabis production in Canada?

Cannara Biotech operates two purpose-built cannabis cultivation facilities totaling more than 1.6 million square feet, allowing the company to grow up to 100 tonnes annually as market demand increases.

Cannabis production at scale requires infrastructure, consistency, and operational control, principles that Cannara Biotech has embedded into its strategy through two purpose-built cultivation facilities: a 1 million-square-foot site in Valleyfield and a 605,000-square-foot facility in Farnham, together forming one of the largest cultivation footprints among Canadian licensed producers.

Current output is approximately 50,000 kilograms of cannabis annually, with the ability to scale to 100,000 kilograms per year as additional cultivation zones are activated.

Cannara is also fully vertically integrated, meaning the company manages the entire process from cultivation through finished product manufacturing and distribution to it’s provincial government partners across Canada. This structure allows tighter control over product consistency, quality, and supply chain efficiency.

The company recently announced it’s uplisting to the TSX as a strategy to improve accessibility for investors and increase visibility in Canadian capital markets.

As Canada’s cannabis market matures, scale, efficiency, and brand consistency remain key competitive advantages for licensed producers.

To learn more about Cannara Biotech (TSX: LOVE, OTCQX: LOVFF)

Watch their video HERE

Published by BTV - The Agency

Discover Investment Opportunities with BTV. Delivering engaging content to Investors for 25+ years.

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.